TSURE
LIVE

Serial Number

79358840

Owner

SANSURE BIOTECH FRANCE

Attorney

Charles Ho

Filing Date

Sep 16, 2022

Add to watchlist:

No watchlists yet
View on USPTO

TSURE Trademark

Serial Number: 79358840 • Registration: 7451947

TSURE is a trademark filed by SANSURE BIOTECH FRANCE on September 16, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

SANSURE BIOTECH FRANCE (2 trademarks)

66 avenue des Champs-Élysées

Entity Type: 99

Trademark Details

Filing Date

September 16, 2022

Registration Date

July 23, 2024

Published for Opposition

May 7, 2024

Goods & Services

diagnostic reagents for medical use; reagents for use in medical genetic testing; medical diagnostic products for bacteriological cultures, namely, medical diagnostic reagents; chemical preparations for pharmaceutical use, namely, for treating infectious diseases, inflammatory and neoplastic diseases, digestive diseases, respiratory diseases, circulatory diseases, immune system diseases; chemical preparations for medical use, namely, for treating infectious diseases, inflammatory and neoplastic diseases, digestive diseases, respiratory diseases, circulatory diseases, immune system diseases; diagnostic preparations for medical use; diagnostic kits for medical diagnostic purposes consisting of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, for the detection of cancer, infectious diseases, inflammatory disorders and oncological disorders; purified biochemicals, namely, protein arrays, fluorescent enzymes and dyes for use as reagents for medical diagnostics; chemical reagents for medical and veterinary use; biochemical preparations for medical use being chemical preparations for the diagnosis of pregnancy; diagnostic biomarking reagents for medical use; all of the aforementioned goods are not for use with infusion sets; ointments for pharmaceutical use being antibiotic ointments; antibiotic ointments; anti-inflammatory ointments; medicinal ointments for treating dermatological conditions; food for babies; dietary supplements for humans and animals for the mouth to be taken in the nature of tablets, capsules and gel capsules; dental waxes

blood testing apparatus; x-ray diagnostic apparatus; testing apparatus for medical use, namely, genetic testing apparatus for medical purposes; diagnostic imaging apparatus for medical use, namely, electromagnetic medical diagnostic imaging apparatus; apparatus for testing bacteria and viruses, namely, medical diagnostic apparatus for testing for viruses and bacteria; DNA extraction and purification apparatus for medical use, namely, apparatus for DNA testing for medical purposes; medical apparatus and instruments for RNA analysis, other than for dental use, namely, apparatus for RNA testing for medical purposes; body composition analyzers for medical use; diagnostic apparatus for medical and veterinary use, in particular for detecting nucleic acid molecules in a sample, in particular in a patient sample, namely, medical apparatus and instruments for diagnostic use for testing for hereditary diseases, infectious diseases, inflammatory and neoplastic diseases, digestive diseases, respiratory diseases, circulatory diseases, immune system diseases; analysis devices for identification of bacteria for medical use, namely, medical instruments for analysing and identifying bacteria; DNA and RNA testing apparatus for medical use; genetic testing apparatus for medical use; medical devices, namely, nucleic acid analyzer for medical diagnostics, namely, medical apparatus and instruments for diagnostic use for testing for hereditary diseases, infectious diseases, inflammatory and neoplastic diseases, digestive diseases, respiratory diseases, circulatory diseases, immune system diseases; immunochemical testing apparatus for medical use; all of the aforementioned goods do not consist of infusion sets, and are not for use with infusion sets

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 7, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 25, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 7, 2025 FICS
FINAL DISPOSITION PROCESSED
Jan 6, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 23, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 23, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 23, 2024 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 30, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 7, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 7, 2024 OPNR
NOTIFICATION PROCESSED BY IB
May 8, 2024 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 7, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 7, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 17, 2024 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 17, 2024 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 17, 2024 OP2R
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Apr 10, 2024 LIMN
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 15, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 15, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 15, 2024 ERFR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 13, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 13, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 13, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 13, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 13, 2024 COAR
LIMITATION OF GOODS RECEIVED FROM IB
Feb 12, 2024 LIMG
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 2, 2024 GNFN
FINAL REFUSAL E-MAILED
Jan 2, 2024 GNFR
FINAL REFUSAL WRITTEN
Jan 2, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 27, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 25, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 25, 2023 TROA
REFUSAL PROCESSED BY IB
Sep 4, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 11, 2023 RFCS
REFUSAL PROCESSED BY MPU
Aug 11, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 7, 2023 RFCR
NON-FINAL ACTION WRITTEN
Jul 6, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 28, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 7, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 3, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 30, 2022 REPR